Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2026 08:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid...
May 18, 2026 08:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing...
May 14, 2026 08:30 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of...
April 23, 2026 01:00 ET | Source: Medidata Solutions, Inc.

Worldwide Clinical Trials and Medidata Announce Strategic Partnership to Embed Medidata AI Across the Full Trial Lifecycle, Bolstering Study Execution and Delivery Excellence

Research Triangle Park, N.C. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Worldwide Clinical Trials, Inc. (Worldwide), a global contract research organization (CRO), and Medidata, a Dassault...
April 21, 2026 16:30 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in...
April 20, 2026 08:00 ET | Source: BioCardia, Inc.

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
April 15, 2026 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
April 01, 2026 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
February 02, 2026 08:30 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood...
January 27, 2026 09:00 ET | Source: Truveta

Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation

BELLEVUE, Wash., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and execute clinical...